Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs

Molecular Pharmaceutics

Volumn 14, Issue 10, 2017, Pages 3248-3257

  Nedelcovych, Michael ^a   Dash, Ranjeet P ^a   Tenora, Lukáš ^b   Zimmermann, Sarah C ^a   Gadiano, Alexandra J ^a   Garrett, Caroline ^a   Alt, Jesse ^a   Hollinger, Kristen R ^a   Pommier, Elie ^a   Jančařík, Andrej ^b   Rojas, Camilo ^a   Thomas, Ajit G ^a   Wu, Ying ^a   Wozniak, Krystyna ^a   Majer, Pavel ^b   Slusher, Barbara S ^a   Rais, Rana ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

2 PMPA; glutamate carboxypeptidase II; intranasal; neurological disease; pharmacokinetics; prodrugs

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; ESTER DERIVATIVE; GAMMA (4 ACETOXYBENZYL) 2 (PHOSPHONOMETHYL)PENTANEDIOC ACID; PRODRUG; UNCLASSIFIED DRUG; 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; ESTER; GLUTAMATE CARBOXYPEPTIDASE II; NEUROPROTECTIVE AGENT; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; LIPOPHILICITY; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; RAT; SCIATIC NERVE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CHEMISTRY; DRUG EFFECT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; RHESUS MONKEY; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; ESTERS; GLUTAMATE CARBOXYPEPTIDASE II; MACACA MULATTA; MALE; NEUROPROTECTIVE AGENTS; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 85030650975     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.7b00231     Document Type: Article

References (39)

1. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer EMBO J. 2006, 25 (6) 1375-84 10.1038/sj.emboj.7600969
2. Slusher, B. S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury Nat. Med. 1999, 5 (12) 1396-402 10.1038/70971
3. Adedoyin, M. O.; Vicini, S.; Neale, J. H. Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model Mol. Pain 2010, 6, 60 10.1186/1744-8069-6-60
4. Kozikowski, A. P.; Zhang, J.; Nan, F.; Petukhov, P. A.; Grajkowska, E.; Wroblewski, J. T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents J. Med. Chem. 2004, 47 (7) 1729-38 10.1021/jm0306226
5. Nagel, J.; Belozertseva, I.; Greco, S.; Kashkin, V.; Malyshkin, A.; Jirgensons, A.; Shekunova, E.; Eilbacher, B.; Bespalov, A.; Danysz, W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-relation to brain concentration Neuropharmacology 2006, 51 (7-8) 1163-71 10.1016/j.neuropharm.2006.07.018
6. Yamamoto, T.; Hirasawa, S.; Wroblewska, B.; Grajkowska, E.; Zhou, J.; Kozikowski, A.; Wroblewski, J.; Neale, J. H. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model Eur. J. Neurosci. 2004, 20 (2) 483-94 10.1111/j.1460-9568.2004.03504.x
7. Yamamoto, T.; Nozaki-Taguchi, N.; Sakashita, Y.; Inagaki, T. Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test Neuroscience 2001, 102 (2) 473-9 10.1016/S0306-4522(00)00502-9
8. Carpenter, K. J.; Sen, S.; Matthews, E. A.; Flatters, S. L.; Wozniak, K. M.; Slusher, B. S.; Dickenson, A. H. Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat Neuropeptides 2003, 37 (5) 298-306 10.1016/j.npep.2003.08.001
9. Zhang, W.; Murakawa, Y.; Wozniak, K. M.; Slusher, B.; Sima, A. A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy J. Neurol. Sci. 2006, 247 (2) 217-23 10.1016/j.jns.2006.05.052
10. Zhang, W.; Slusher, B.; Murakawa, Y.; Wozniak, K. M.; Tsukamoto, T.; Jackson, P. F.; Sima, A. A. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats J. Neurol. Sci. 2002, 194 (1) 21-8 10.1016/S0022-510X(01)00670-0
11. Olszewski, R. T.; Bzdega, T.; Neale, J. H. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia Schizophrenia research 2012, 136 (1-3) 160-1 10.1016/j.schres.2012.01.007
12. McKinzie, D. L.; Li, T. K.; McBride, W. J.; Slusher, B. S. NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats Addict. Biol. 2000, 5 (4) 411-6 10.1111/j.1369-1600.2000.tb00209.x
13. Shippenberg, T. S.; Rea, W.; Slusher, B. S. Modulation of behavioral sensitization to cocaine by NAALADase inhibition Synapse (Hoboken, NJ, U. S.) 2000, 38 (2) 161-6 10.1002/1098-2396(200011)38:2<161::AID-SYN7>3.0.CO;2-G
14. Xi, Z. X.; Kiyatkin, M.; Li, X.; Peng, X. Q.; Wiggins, A.; Spiller, K.; Li, J.; Gardner, E. L. N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats Neuropharmacology 2010, 58 (1) 304-13 10.1016/j.neuropharm.2009.06.016
15. Ha, D.; Bing, S. J.; Ahn, G.; Kim, J.; Cho, J.; Kim, A.; Herath, K. H.; Yu, H. S.; Jo, S. A.; Cho, I. H.; Jee, Y. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis FEBS J. 2016, 283 (18) 3438-56 10.1111/febs.13816
16. Hollinger, K. R.; Alt, J.; Riehm, A. M.; Slusher, B. S.; Kaplin, A. I. Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis Brain Res. 2016, 1635, 105-12 10.1016/j.brainres.2016.01.035
17. Rahn, K. A.; Watkins, C. C.; Alt, J.; Rais, R.; Stathis, M.; Grishkan, I.; Crainiceau, C. M.; Pomper, M. G.; Rojas, C.; Pletnikov, M. V.; Calabresi, P. A.; Brandt, J.; Barker, P. B.; Slusher, B. S.; Kaplin, A. I. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (49) 20101-6 10.1073/pnas.1209934109
18. Feng, J. F.; Gurkoff, G. G.; Van, K. C.; Song, M.; Lowe, D. A.; Zhou, J.; Lyeth, B. G. NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia Brain Res. 2012, 1469, 144-52 10.1016/j.brainres.2012.06.021
19. Gao, Y.; Xu, S.; Cui, Z.; Zhang, M.; Lin, Y.; Cai, L.; Wang, Z.; Luo, X.; Zheng, Y.; Wang, Y.; Luo, Q.; Jiang, J.; Neale, J. H.; Zhong, C. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury J. Neurochem. 2015, 134 (2) 340-53 10.1111/jnc.13123
20. Neale, J. H. N-acetylaspartylglutamate is an agonist at mGluR(3) in vivo and in vitro J. Neurochem. 2011, 119 (5) 891-5 10.1111/j.1471-4159.2011.07380.x
21. Cao, Y.; Gao, Y.; Xu, S.; Bao, J.; Lin, Y.; Luo, X.; Wang, Y.; Luo, Q.; Jiang, J.; Neale, J. H.; Zhong, C. Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury BMC Neurosci. 2016, 17, 15 10.1186/s12868-016-0251-1
22. Barinka, C.; Rojas, C.; Slusher, B.; Pomper, M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer Curr. Med. Chem. 2012, 19 (6) 856-70 10.2174/092986712799034888
23. Majer, P.; Jancarik, A.; Krecmerova, M.; Tichy, T.; Tenora, L.; Wozniak, K.; Wu, Y.; Pommier, E.; Ferraris, D.; Rais, R.; Slusher, B. S. Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA) J. Med. Chem. 2016, 59, 2810-9 10.1021/acs.jmedchem.6b00062
24. Rais, R.; Wozniak, K.; Wu, Y.; Niwa, M.; Stathis, M.; Alt, J.; Giroux, M.; Sawa, A.; Rojas, C.; Slusher, B. S. Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration PLoS One 2015, 10 (7) e0131861 10.1371/journal.pone.0131861
25. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors J. Med. Chem. 2001, 44 (24) 4170-5 10.1021/jm0001774
26. Stoermer, D.; Liu, Q.; Hall, M. R.; Flanary, J. M.; Thomas, A. G.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II Bioorg. Med. Chem. Lett. 2003, 13 (13) 2097-100 10.1016/S0960-894X(03)00407-4
27. Dhuria, S. V.; Hanson, L. R.; Frey, W. H., 2nd Intranasal delivery to the central nervous system: mechanisms and experimental considerations J. Pharm. Sci. 2010, 99 (4) 1654-73 10.1002/jps.21924
28. Hin, B.; Majer, P.; Tsukamoto, T. Facile synthesis of alpha-substituted acrylate esters J. Org. Chem. 2002, 67 (21) 7365-8 10.1021/jo026101s
29. Barinka, C.; Rinnova, M.; Sacha, P.; Rojas, C.; Majer, P.; Slusher, B. S.; Konvalinka, J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II J. Neurochem. 2002, 80 (3) 477-87 10.1046/j.0022-3042.2001.00715.x
30. Bailer, A. J. Testing for the equality of area under the curves when using destructive measurement techniques J. Pharmacokinet. Biopharm. 1988, 16 (3) 303-9 10.1007/BF01062139
31. Nedelman, J. R.; Gibiansky, E.; Lau, D. T. W. Applying Bailer's Method for AUC Confidence Intervals to Sparse Sampling Pharm. Res. 1995, 12 (1) 124-128 10.1023/A:1016255124336
32. Yuan, J. Estimation of variance for AUC in animal studies J. Pharm. Sci. 1993, 82 (7) 761-3 10.1002/jps.2600820718
33. Vornov, J. J.; Hollinger, K. R.; Jackson, P. F.; Wozniak, K. M.; Farah, M. H.; Majer, P.; Rais, R.; Slusher, B. S. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors Adv. Pharmacol. 2016, 76, 215-55 10.1016/bs.apha.2016.01.007
34. Kao, H. D.; Traboulsi, A.; Itoh, S.; Dittert, L.; Hussain, A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs Pharm. Res. 2000, 17 (8) 978-84 10.1023/A:1007583422634
35. Aungst, B. J.; Hussain, M. A., Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration; Google Patents; 1987.
36. Hussain, A. A.; AL-Bayatti, A. A.; Dakkuri, A.; Okochi, K.; Hussain, M. A. Testosterone 17β-N, N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone J. Pharm. Sci. 2002, 91 (3) 785-789 10.1002/jps.10083
37. Rais, R.; Rojas, C.; Wozniak, K.; Wu, Y.; Zhao, M.; Tsukamoto, T.; Rudek, M. A.; Slusher, B. S. Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) J. Pharm. Biomed. Anal. 2014, 88, 162-9 10.1016/j.jpba.2013.08.028
38. Lochhead, J. J.; Thorne, R. G. Intranasal delivery of biologics to the central nervous system Adv. Drug Delivery Rev. 2012, 64 (7) 614-628 10.1016/j.addr.2011.11.002
39. Nagaya, Y.; Nozaki, Y.; Takenaka, O.; Watari, R.; Kusano, K.; Yoshimura, T.; Kusuhara, H. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats Drug Metab. Pharmacokinet. 2016, 31 (1) 57-66 10.1016/j.dmpk.2015.10.003